INTRODUCTION
Investigations into compounds that have demonstrated effectiveness against the carcinogenesis process have a rather long history. Studies of animal tumor models have progressively grown in number; several compounds have been demonstrated to be active and the multiplicity of experimental models has progressively increased. Sporn and Newton have introduced the concept of cancer chemoprevention in humans (1) . This has rapidly become one of the most promising fields in experimental and clinical oncology.
CHEMOPREVENTIVE AGENTS IN COLORECTAL CANCER
Several classes of chemicals have potential chemopreventive efficacy in colon cancer (2) . Many of them are naturally occurring constituents of food. These compounds have been classified according to their probable sites of action during the multistage carcinogenesis process. Usually they are subdivided into two main categories: inhibitors of tumor-initiating agents and inhibitors of tumor promoters. In the first category there are compounds that prevent carcinogen formation from precursors (i.e. ascorbic acid, α-tocopherols, plant phenols), agents that inhibit the reaction of carcinogens with cellular targets (phenols, flavonoids, isothiocyanates), and compounds that inhibit the emergence of neoplasia after exposure to carcinogenic agents (retinoids, carotenoids, selenium, protease inhibitors, inhibitors of arachidonic acid metabolism, sterols). The second group includes retinoids, protease inhibitors, inhibitors of arachidonic acid metabolism, agents increasing cAMP, calcium and modulators of calcium metabolism.
Among the compounds with potential chemopreventive efficacy, retinoids and carotenoids (vitamin A), ascorbic acid (vitamin C) and tocopherol (vitamin E) have been studied extensively. These micronutrients inactivate free radicals, thus limiting DNA damage and maturation. However, their mechanism of action is more complex than simple antioxidant activity. Experimental studies have demonstrated that vitamin A and its analogues are able to modulate the proliferation and differentiation of normal, premalignant and malignant cells in vivo and in vitro. Ascorbic acid is also able to inhibit chemically-induced transformation of mouse embryo cells in vitro (3). The laboratory evidence is supported by epidemiological studies. An inverse relationship was found between the intake of vitamin A or carotenoids and the incidence of upper digestive tract cancer (4) .
Epidemiological evidence also suggests a protective effect of dietary fibers. Fibers can lower the pH of the intestinal lumen and inhibit the growth of potentially harmful bacteria (5) . Moreover, fibers reduce the bowel transit time and reduce the duration of contact of carcinogens with the mucosa. At the same time they dilute the carcinogens in the feces.
In the last few years attention has been focused on calcium. The potential chemopreventive activity of this substance has been strongly supported by in vitro studies on the proliferation and differentiation of epithelial cells, and in vivo studies utilizing biomarkers of colonic epithelial cell proliferation in rodents and humans.
Aspirin and other nonsteroidal anti-iflammatory drugs are under investigation. Studies in humans have shown that sulindac administration decreases the number and size of colorectal adenomas in patients affected by familial adenomatous polyposis (FAP). In a retrospective study, aspirin has been indicated as a potential chemopreventive agent able to reduce colorectal cancer mortality.
Today, selective cyclooxygenase-2 inhibitors are of interest for their tolerability and efficacy (6) . In FAP, the use of celecoxib (400 mg twice a day) causes a reduction of the number of colorectal adenomas (7) . The same holds true for duodenal adenomas, which also are a frequent finding in FAP (8) .
INTERMEDIATE ENDPOINTS
Phase I studies examine the safety and toxicity of chemopreventive compounds. Phase II trials evaluate the Seragnoli Institute, University of Bologna, Bologna -Italy activity of chemopreventive substances in subjects at high risk of cancer. Phase III trials evaluate the effect of chemoprevention regimens on reduction of the cancer incidence. Several years of study and a large population sample are needed to determine the efficacy of a given substance. The consequence is that research is mainly focused on the reversal or prevention of early molecular and cellular events that are directly associated with the development of cancer, utilized as surrogate endpoints.
In the past few years abnormalities of cell proliferation and differentiation have been considered as intermediate biomarkers useful as surrogate endpoints in cancer chemoprevention studies (9) . An increase in the proliferative indices of the cells in the rectal crypts and enlargement of the proliferative compartments, usually confined to the lower two thirds of the crypts themselves, are considered biological indicators of proneness to cancer development. These alterations are frequently found in apparently normal mucosa of patients affected by large bowel adenomas or cancer (9) . Some findings suggest that antioxidant vitamins (A, C, E) or calcium supplementation in patients with large bowel adenomas and folic acid supplementation in patients with ulcerative colitis are effective in reducing abnormalities in cell kinetics that may be indicative of a precancerous condition (9) (10) (11) (12) .
As adenomas represent the most frequent precursors of colorectal cancer, the prevention of their recurrence may represent another useful endpoint of chemoprevention studies. Dietary supplementation with vitamins C and E was shown to result in a trend towards reduction in the recurrence of adenomas in population groups at risk for cancer in two international multicenter studies of chemoprevention in relapsing colonic adenomas (sporadic type).
An interesting point for future studies will be to demonstrate the relationship between exogenous factors and DNA rearrangements. Genetic abnormalities could represent a marker of damage that would be useful as a surrogate endpoint in clinical trials.
THE GENE-ENVIRONMENT INTERACTION: THE EXAMPLE OF MTHFR GENE ALTERATIONS
Reduced bioavailability of folates causes an increase in the risk of tumor development, in particular colorectal cancer (13, 14) . These conclusions have been reached primarily by means of food frequency questionnaires and biochemical and radioimmunological determination of the folate concentration in serum and in erythrocytes (15) .
Folic acid is an important coenzyme for the synthesis of purines and pyrimidines, for the metabolism of different amino acids and biogenic amines, and for the initiation of protein synthesis (16, 17) . Several of these metabolic pathways are closely linked to DNA synthesis and, as a consequence, to a correct order of cellular proliferation processes.
The analytic validity of biochemical indices of nutritional states is influenced by genotype. Analogously, the bioavailability of folates in the organism is not only related to their uptake with the diet but also depends on the genetic and metabolic characteristics of the individual. This is illustrated by the genetic basis of the control of the activity of methylenetetrahydrofolate reductase (MTHFR). At the moment, the major interest in the area of gene-environment interaction is focused on the relationship between colorectal cancer risk, folate intake and genetic variants, associated with different folate metabolism (18) (19) (20) (21) . The MTHFR C677T polymorphism is the most extensively studied variant in this respect. In a chemoprevention trial high folate doses were administered to patients with MTHFR gene alterations and the cellular kinetics of the rectal mucosa was taken as an indicator of effectiveness. This study suggests that folate administration contributes to the cytoproliferative state of the rectal mucosa (10) .
CONCLUSIONS
The available data indicate that chemoprevention is becoming a reliable tool in the primary prevention of colorectal cancer. Some controversies still exist, and further trials are required to assess the relative efficacy of the available chemopreventive agents administered alone or in combination, as well as their optimal dosage. Particular attention should be paid to the assessment of specific stages of abnormal cell development and differentiation, as different chemopreventive agents act at different stages of tumor growth and through different mechanisms.
